Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

Background A recent study showed that tolvaptan, a vasopressin V2 receptor antagonist, decreased total kidney volume (TKV) growth and estimated glomerular filtration rate (GFR) loss in autosomal dominant polycystic kidney disease (ADPKD) with creatinine clearance ≥ 60 mL/min. The aim of our study wa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 2015-06, Vol.65 (6), p.833-841
Hauptverfasser:	Boertien, Wendy E., MD, PhD, Meijer, Esther, MD, PhD, de Jong, Paul E., MD, PhD, ter Horst, Gert J., MSc, PhD, Renken, Remco J., MSc, PhD, van der Jagt, Eric J., MD, PhD, Kappert, Peter, MSc, Ouyang, John, MSc, Engels, Gerwin E., MSc, PhD, van Oeveren, Willem, MSc, PhD, Struck, Joachim, MSc, Czerwiec, Frank S., MD, PhD, Oberdhan, Dorothee, MSc, Krasa, Holly B., MSc, Gansevoort, Ron T., MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Kidney Injury - metabolism Adult Antidiuretic Hormone Receptor Antagonists - therapeutic use Autosomal dominant polycystic kidney disease (ADPKD) Benzazepines - therapeutic use Biomarkers - metabolism Cohort Studies Disease Progression drug efficacy Enzyme-Linked Immunosorbent Assay Female Glomerular Filtration Rate glomerular filtration rate (GFR) Glycopeptides - blood Humans Kidney - pathology kidney function Magnetic Resonance Imaging Male Middle Aged Nephrology Organ Size Osmolar Concentration Polycystic Kidney, Autosomal Dominant - complications Polycystic Kidney, Autosomal Dominant - drug therapy Polycystic Kidney, Autosomal Dominant - metabolism Prospective Studies Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - etiology Renal Insufficiency, Chronic - metabolism Severity of Illness Index tolvaptan Treatment Outcome vasopressin V2 receptor antagonist
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!